WO1996013593A3 - Soluble single chain t cell receptors - Google Patents
Soluble single chain t cell receptors Download PDFInfo
- Publication number
- WO1996013593A3 WO1996013593A3 PCT/US1995/013770 US9513770W WO9613593A3 WO 1996013593 A3 WO1996013593 A3 WO 1996013593A3 US 9513770 W US9513770 W US 9513770W WO 9613593 A3 WO9613593 A3 WO 9613593A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tcr
- single chain
- fusion protein
- soluble
- proteins
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 abstract 6
- 102000037865 fusion proteins Human genes 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000009257 reactivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A fusion protein, comprising a carrier protein connected by a peptide tether to a single chain T cell receptor molecule, consisting of a Vα segment linked to a Vβ segment of the T cell receptor, is disclosed. Also disclosed is a soluble single chain T cell receptor molecule with a conformation that is essentially functionally indistinguishable, based upon reactivity to clonotype-specific antibodies, from that appearing on the surface of T cells. The invention also concerns nucleic acid fragments encoding the fusion protein, expression vectors comprising a nucleic acid fragment encoding the fusion protein, host cells containing such expression vectors, and antibodies to the single chain T cell receptor or to the fusion protein. The invention further pertains to methods of isolating and purifying the fusion proteins, as well as isolating and purifying soluble, single chain T cell receptors. In addition the invention pertains to various uses of soluble TCR fusion protein and isolated single chain TCR. The proteins can be used in molecular assays designed to measure their binding to ligands, including MHC/HLA-peptide antigen complexes or TCR-specific antibodies. Such assays are useful for the detection of agents that block the TCR-ligand interaction. The soluble TCR proteins can also be used to immunize animals, including humans, to produce TCR-specific antibodies. In addition, either in their native or denatured conformation the proteins can be used to vaccinate animals, including humans, in order to suppress the immune response of T cells bearing TCR that share antigenic epitopes with the vaccinating protein.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32931094A | 1994-10-26 | 1994-10-26 | |
| US08/329,310 | 1994-10-26 | ||
| US34789394A | 1994-12-01 | 1994-12-01 | |
| US08/347,893 | 1994-12-01 | ||
| US46813195A | 1995-06-06 | 1995-06-06 | |
| US08/468,131 | 1995-06-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1996013593A2 WO1996013593A2 (en) | 1996-05-09 |
| WO1996013593A3 true WO1996013593A3 (en) | 1996-08-01 |
Family
ID=27406656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1995/013770 WO1996013593A2 (en) | 1994-10-26 | 1995-10-26 | Soluble single chain t cell receptors |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1996013593A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039482A1 (en) * | 1997-03-07 | 1998-09-11 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
| US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| ATE533784T1 (en) * | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | SOLUBLE, SINGLE-CHAIN T-CELL RECEPTOR PROTEINS |
| EP1047781B1 (en) * | 1998-01-23 | 2004-07-28 | Immunex Corporation | Il-18 receptors |
| EP1289564B1 (en) * | 2000-06-05 | 2018-07-18 | Altor BioScience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| DK1546188T3 (en) | 2001-06-05 | 2008-10-27 | Altor Bioscience Corp | P53-binding T cell receptor molecules and uses thereof |
| AU2008206442B2 (en) | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
| CA2945816A1 (en) | 2014-04-15 | 2015-10-22 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| AU2016363696B2 (en) * | 2015-12-02 | 2021-05-20 | Innovative Targeting Solutions Inc. | Single variable domain T-cell receptors |
| MX2018013445A (en) | 2016-05-06 | 2019-09-09 | Juno Therapeutics Inc | Genetically engineered cells and methods of making the same. |
| MA45491A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
| WO2018005559A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| US11896615B2 (en) | 2016-10-13 | 2024-02-13 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
| CA3040914A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| BR112019011025A2 (en) | 2016-12-03 | 2019-10-08 | Juno Therapeutics Inc | T cell modulation methods |
| ES2961666T3 (en) | 2016-12-03 | 2024-03-13 | Juno Therapeutics Inc | Methods to determine CAR-T cell dosage |
| WO2018106732A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| EP3568414A1 (en) | 2017-01-10 | 2019-11-20 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
| MX2019008538A (en) | 2017-01-20 | 2019-11-05 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods. |
| US11845803B2 (en) | 2017-02-17 | 2023-12-19 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| BR112019017767A2 (en) | 2017-02-27 | 2020-04-07 | Juno Therapeutics Inc | compositions, articles of manufacture and methods related to dosing in cell therapy |
| SG11201908271WA (en) | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| MX2019012189A (en) | 2017-04-14 | 2020-12-10 | Juno Therapeutics Inc | Methods for assessing cell surface glycosylation. |
| PT3618842T (en) | 2017-05-01 | 2024-01-12 | Juno Therapeutics Inc | Combination of a cell therapy and an immunomodulatory compound |
| AU2018275891A1 (en) | 2017-06-02 | 2019-12-12 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
| KR20200054160A (en) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | Preparation and method of articles for treatment with adoptive cell therapy |
| CA3067602A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| MX2020000900A (en) | 2017-07-29 | 2021-01-08 | Juno Therapeutics Inc | Reagents for expanding cells expressing recombinant receptors. |
| MX2020001491A (en) | 2017-08-09 | 2020-08-06 | Juno Therapeutics Inc | Methods and compositions for preparing genetically engineered cells. |
| US11851678B2 (en) | 2017-08-09 | 2023-12-26 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| WO2019046832A1 (en) | 2017-09-01 | 2019-03-07 | Juno Therapeutics, Inc. | Gene expression and assessment of risk of developing toxicity following cell therapy |
| US20200292526A1 (en) | 2017-09-07 | 2020-09-17 | Juno Therapeutics, Inc. | Methods of identifying cellular attributes related to outcomes associated with cell therapy |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| AU2018360801A1 (en) | 2017-11-01 | 2020-05-14 | Celgene Corporation | Process for producing a T cell composition |
| MX2020004240A (en) | 2017-11-01 | 2020-09-25 | Juno Therapeutics Inc | Process for generating therapeutic compositions of engineered cells. |
| WO2019089884A2 (en) | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| CN111556893A (en) | 2017-11-06 | 2020-08-18 | 爱迪塔斯医药股份有限公司 | Methods, compositions, and components for CRISPR-CAS9 editing of CBLB in immunotherapy T cells |
| WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| GB201719169D0 (en) | 2017-11-20 | 2018-01-03 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor and ligand |
| KR20200116081A (en) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods of administration and control of genetically engineered cells |
| WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| AU2018379092A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Process for producing a composition of engineered T cells |
| BR112020011223A2 (en) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | phenotypic markers for cell therapy and related methods |
| WO2019152743A1 (en) | 2018-01-31 | 2019-08-08 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| WO2019195492A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| PE20201345A1 (en) | 2018-04-05 | 2020-11-25 | Juno Therapeutics Inc | RECEIVERS OF T-CELLS, AND DESIGNED CELLS THAT EXPRESS THEM |
| JP2021520211A (en) | 2018-04-05 | 2021-08-19 | ジュノー セラピューティクス インコーポレイテッド | T cells expressing recombinant receptors, related polynucleotides, and methods |
| MX2021001519A (en) | 2018-08-09 | 2021-05-27 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids. |
| CA3108657A1 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| EP3850366A1 (en) | 2018-09-11 | 2021-07-21 | Juno Therapeutics, Inc. | Methods for mass spectrometry analysis of engineered cell compositions |
| CA3117568A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| ES2968737T3 (en) | 2018-11-06 | 2024-05-13 | Juno Therapeutics Inc | Process to produce genetically engineered T cells |
| KR20210111247A (en) | 2018-11-08 | 2021-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods and Combinations for Treatment and Modulation of T Cells |
| CA3120869A1 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| FI3886894T3 (en) | 2018-11-30 | 2024-05-24 | Juno Therapeutics Inc | Methods for dosing and treatment of b cell malignancies in adoptive cell therapy |
| SG11202111360YA (en) | 2019-05-01 | 2021-11-29 | Juno Therapeutics Inc | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| BR112021024404A2 (en) | 2019-06-07 | 2022-04-19 | Juno Therapeutics Inc | Automated t cell culture |
| SG11202113356XA (en) | 2019-06-12 | 2021-12-30 | Juno Therapeutics Inc | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| BR112022008023A2 (en) | 2019-10-30 | 2022-07-12 | Juno Therapeutics Gmbh | CELL SELECTION AND/OR STIMULATION DEVICES AND USE METHODS |
| AU2020395318A1 (en) | 2019-12-06 | 2022-06-09 | Juno Therapeutics, Inc. | Methods related to toxicity and response associated with cell therapy for treating B cell malignancies |
| CN115427550A (en) | 2020-01-28 | 2022-12-02 | 朱诺治疗学股份有限公司 | T cell transduction methods |
| AU2021243864A1 (en) | 2020-03-27 | 2022-11-03 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US20210322471A1 (en) | 2020-03-27 | 2021-10-21 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
| US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| WO2022060904A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
| WO2022084415A1 (en) | 2020-10-20 | 2022-04-28 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods and compositions for treating epstein barr virus-associated cancer |
| EP4240405A1 (en) | 2020-11-05 | 2023-09-13 | Mendus B.V. | Use of tumor-independent antigens in immunotherapies |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| EP4301755A1 (en) | 2021-03-03 | 2024-01-10 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| KR20230159851A (en) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | How to Determine the Potency of a Therapeutic Cell Composition |
| KR20240005700A (en) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Dosing and Treatment Methods Using Combination of Checkpoint Inhibitor Therapy and CAR T Cell Therapy |
| WO2022234009A2 (en) | 2021-05-06 | 2022-11-10 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| EP4370540A2 (en) | 2021-07-12 | 2024-05-22 | Ludwig Institute for Cancer Research Ltd | T cell receptors specific for tumor-associated antigens and methods of use thereof |
| WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2024006960A1 (en) | 2022-06-29 | 2024-01-04 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018019A1 (en) * | 1990-05-15 | 1991-11-28 | E.R. Squibb & Sons, Inc. | Soluble single chain t cell receptors |
| WO1992001715A1 (en) * | 1990-07-19 | 1992-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Soluble cell-surface dimeric proteins |
| WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
-
1995
- 1995-10-26 WO PCT/US1995/013770 patent/WO1996013593A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991018019A1 (en) * | 1990-05-15 | 1991-11-28 | E.R. Squibb & Sons, Inc. | Soluble single chain t cell receptors |
| WO1992001715A1 (en) * | 1990-07-19 | 1992-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Soluble cell-surface dimeric proteins |
| WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
Non-Patent Citations (8)
| Title |
|---|
| C. WONG ET AL.: "Single chain T cell receptor as a tumor specific vaccine.", THE FASEB JOURNAL, vol. 9, no. 3, 9 March 1995 (1995-03-09), BETHESDA, MD, USA, pages A514, XP002002800 * |
| D. LAKE ET AL.: "Construction and serological characterization of a recombinant human single chain T cell receptor.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 201, no. 3, 30 June 1994 (1994-06-30), DULUTH, MN, USA, pages 1502 - 1509, XP002002799 * |
| J. NEWCOMB ET AL.: "Demonstration of soluble T cell receptor function using proliferation-based assays. In: THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. San Francisco, July 23-29, 1995. Abstract book.", 1995, SAN FRANCISCO, CA, USA, XP002002801 * |
| J. NOVOTNY ET AL.: "A soluble single chain T cell receptor fragment endowed with antigen-combining properties.", THE FASEB JOURNAL, vol. 6, no. 1, 1 January 1992 (1992-01-01), BETHESDA, MD, USA, pages A351, XP002002795 * |
| J. NOVOTNY ET AL.: "A soluble, single-chain T cell receptor fragment endowed with antigen-combining properties.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 19, 1 October 1991 (1991-10-01), WASHINGTON, DC, USA, pages 8646 - 8650, XP002002796 * |
| M. JESSON ET AL.: "Immunogenicity of recombinant, soluble T cell receptors in syngeneic mice. In: THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. San Francisco, July 23-29, 1995. Abstract book.", 1995, SAN FRANCISCO, CA, USA, XP002002802 * |
| P. FINK ET AL.: "Correlations between T-cell specificity and the structure of the antigen receptor.", NATURE, vol. 321, 15 May 1986 (1986-05-15), LONDON, GB, pages 219 - 226, XP002002798 * |
| W. SOO HOO ET AL.: "Characterization of a single-chain T-cell receptor expressed in Escherichia coli.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 89, no. 10, 15 May 1992 (1992-05-15), WASHINGTON, DC, USA, pages 4759 - 4763, XP002002797 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996013593A2 (en) | 1996-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996013593A3 (en) | Soluble single chain t cell receptors | |
| Yonemasu et al. | C1q: rapid purification method for preparation of monospecific antisera and for biochemical studies | |
| Mestecky et al. | Studies on human secretory immunoglobulin A: II. Subunit structure | |
| Ljungberg et al. | The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F (ab') 2: separation of affinity from specificity | |
| NO934801D0 (en) | CTL4A receptor, fusion proteins containing it and its use | |
| Sharon et al. | Possible association between IL-2 receptors and class I HLA molecules on T cells. | |
| Jemmerson et al. | Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome. | |
| FI940270A0 (en) | Methods for Regulating the Immune Response Using CTLA4 Binding Molecules and IL4 Binding Molecules | |
| Butler | Antibody-antigen and antibody-hapten reactions | |
| Smith et al. | The preparation and characterization of anti-peptide heteroantisera recognizing subregions of the intracytoplasmic domain of class I H-2 antigens | |
| Ball Jr et al. | Immunochemical studies of (Na++ K+)-ATPase using site-specific, synthetic peptide directed antibodies | |
| WO1996021028A3 (en) | Soluble heterodimeric t cell receptors and their antibodies | |
| Turner et al. | Pepsin digestion of human G-myeloma proteins of different subclasses. II. Immunochemical investigations of the products of peptic digestion | |
| Grey et al. | The subunit structure of mouse IgA | |
| Cunningham et al. | Structure of murine histocompatibility antigens | |
| Givol et al. | Isolation and fragmentation of antibodies to polytyrosyl gelatin | |
| Wedderburn et al. | Single-step immunosorbent preparation of F-protein from mouse liver with conservation of the allo-antigenic site, and determination of concentration in liver and serum | |
| Eilat et al. | Secretion of a soluble, chimeric gamma delta T-cell receptor-immunoglobulin heterodimer. | |
| Tragardh et al. | Chemical, physical-chemical, and immunological properties of papain-solubilized human transplantation antigens | |
| Szelke | Raising antibodies to small peptides | |
| Lögdberg et al. | Binding of mammalian β2-microglobulin by glycoproteins in fish serum | |
| Patil et al. | Detection of mycobacterial antigens in leprosy serum immune complex | |
| Chersi et al. | Generation of rabbit antipeptide antibodies to HLA-class II antigens by the use of synthetic peptides. | |
| Zeng et al. | A novel approach to experimentally estimating the number of reactive epitopes on multivalent antigens | |
| Carrel et al. | Studies on sheep anti-human IgG antibodies and their sub-units |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP MX |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |